ILMN - Illumina - Stock Forecast

Coverage Profile Stock analysts Price Targets & Ratings Chart Insider Trading

ILMN is currently covered by 17 analysts with an average price target of $188.92. This is a potential upside of -$104.77 (-35.67%) from yesterday's end of day stock price of $293.69.

Illumina's activity chart (see below) currently has 734 price targets and 529 ratings on display. The stock rating distribution of ILMN is 50.94% BUY, 35.85% HOLD and 13.21% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 84.39% with an average time for these price targets to be met of 290.17 days.

Highest price target for ILMN is $310, Lowest price target is $95, average price target is $188.92.

Most recent stock forecast was given by DAN LEONARD from RBC. First documented stock forecast 03-Jan-2013.

Overview

Illumina is a life science tools and integrated systems company that focuses on large-scale analysis of genetic variation and function. The company operates through two segments, Core Illumina and GRAIl:

  • The Core Illumina segment develops and markets genomic analysis products and services. This segment’s products are used for applications such as cancer research, reproductive and genetic health, and agriculture.
  • The GRAIL segment focuses on developing multi-cancer early detection tests using Illumina’s sequencing technology. The GRAIL segment aims to develop blood tests that can detect multiple types of cancer at an early stage.

The company’s Galleri test is a multi-cancer early detection test that can detect more than 50 types of cancer through a simple blood draw.

In addition to its products, Illumina provides a range of services including whole-genome sequencing, genotyping, non-invasive prenatal testing (NIPT), and product support services.

History

Illumina was incorporated in 1998 and is headquartered in San Diego, California.

Currently out of the existing stock ratings of ILMN, 27 are a BUY (50.94%), 19 are a HOLD (35.85%), 7 are a SELL (13.21%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 14-May-2026

$310

$16.31 (5.55%)

$230

Buy Since 13-Dec-2023

$305

$11.31 (3.85%)

$226

Buy Since 07-Feb-2023

$300

$6.31 (2.15%)

$210

7 days ago
(28-Sep-2026)

27/30 (90%)

$28 (10.29%)

498

Buy Since 12-Oct-2020

$305

$11.31 (3.85%)

$225

8 days ago
(27-Sep-2026)

24/31 (77.42%)

$33.1 (12.17%)

618

Hold Since 08-Sep-2026

$260

$-33.69 (-11.47%)

$150

27 days ago
(08-Sep-2026)

18/18 (100%)

$55 (26.83%)

207

Show more analysts

Please expand the browser size to see the chart

What is ILMN (Illumina) average time for price targets to be met?

On average it took 290 days for the stock forecasts to be reached, with an average price target met ratio of 84.39%.

Which analyst most recently updated their price target on ILMN (Illumina)?

Dan Leonard

Which analyst has the most public recommendations on ILMN (Illumina)?

Dan Leonard works at RBC and has 37 price targets and 21 ratings on ILMN

Which analyst is the currently most bullish on ILMN (Illumina)?

Steven Mah with the highest potential upside of $251.06

Which analyst is the currently most reserved on ILMN (Illumina)?

Patrick Donnelly with the lowest potential downside of -$198.69
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?